GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
3 of 4 strong
The short version
- Company maintains top-line guidance of 3% to 4% organic sales growth for 2026, reflecting healthy global customer demand and a good start to the year. - Adjusted EPS guidance for 2026 is $4.80 to $5.00 per share, representing approximately 5% to 9% growth year-over-year.
From GE HealthCare Technologies Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Company maintains top-line guidance of 3% to 4% organic sales growth for 2026, reflecting healthy global customer demand and a good start to the year.
- Strong momentum in new product innovations expected to drive more meaningful revenue starting in 2027, especially from Precision Care pipeline in CT and MR modalities.
- Radiopharmaceutical portfolio growing well, with Flyrcado doses increasing nearly 80% since late January and a medium-term target of $500 million+ annual revenue by 2028.
- Capital equipment market remains healthy with robust order growth and record backlog supporting revenue acceleration in the second half of the year.
- Intelerad acquisition expands cloud capabilities and is expected to accelerate sales growth beyond 2026.
- New anesthesia product expected to support Patient Care Solutions improvement in the second half of 2026.
2 more points from GE HealthCare Technologies Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what GE HealthCare Technologies Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans to continue investing organically in the business, with an emphasis on R&D to drive future growth (Page 13).
- They maintain appropriate investment levels to support innovation and pipeline progress, ensuring the business moves forward (Page 13).
- Disciplined M&A is part of their capital deployment strategy, exemplified by the recent Intelerad acquisition to enhance cloud capabilities and outpatient networks (Pages 10, 13).
2 more points from GE HealthCare Technologies Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what GE HealthCare Technologies Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Orders grew 1.1% in the first quarter, following 10.3% growth in the year-ago period (Page 3).
- Book-to-bill ratio was 1.07x for the quarter, indicating strong order intake relative to shipments (Page 3 & 5).
- The backlog reached a record $21.8 billion, up $1.2 billion year-over-year (Page 3).
- Capital equipment orders shown strong performance; the book-to-bill was well north of 1.1 in capital orders specifically (Page 5).
2 more points from GE HealthCare Technologies Inc.'s call on order book
Create a free account to keep reading this call
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
GE HealthCare Technologies Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were GE HealthCare Technologies Inc. Q2 FY26 results?
- Company maintains top-line guidance of 3% to 4% organic sales growth for 2026, reflecting healthy global customer demand and a good start to the year. - Adjusted EPS guidance for 2026 is $4.80 to $5.00 per share, representing approximately 5% to 9% growth year-over-year.
What is GE HealthCare Technologies Inc. share price analysis?
GE HealthCare Technologies Inc. currently shows a neutral. The stock trades at a P/E of 15.4 with a market cap of $28,594. Investors should review the full earnings analysis for detailed insights.
Is GE HealthCare Technologies Inc. planning capital expenditure?
- The company plans to continue investing organically in the business, with an emphasis on R&D to drive future growth (Page 13).
Keep GE HealthCare Technologies Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.